跳至主要内容
临床试验/NL-OMON53345
NL-OMON53345招募中不适用

Development of minimally invasive methodology for diabetyping to personalise treatment to realise remission and reversal of type 2 diabetes. - 2DIAREM

TNO0 个研究点目标入组 57 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
57

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - - Diagnosed with (pre)diabetes type 2;
  • o BMI >=27 kg/m2, including a heterogenous group of people with
  • overweight/prediabetes (without glucose lowering medication), and/or type 2
  • diabetes with or without glucose lowering medication.
  • - Aged 40 years or older
  • - Able and willing to sign the informed consent form
  • - Willing to comply with all study procedures

排除标准

  • - Type 1 diabetes
  • - Latent Autoimmune Diabetes (LADA)
  • - Skin allergy, eczema or known sensitivity for adhesives
  • - History of bariatric weight loss surgery
  • - Planned (bariatric) surgery during the 3 weeks monitoring period with the CGM
  • - Active cancer or chemotherapy or radiation within 2 years prior to
  • participation
  • - A condition that would need an MRI during the 3 weeks monitoring period with
  • - Planned holiday during the 3 week GCM monitoring period
  • - (Night)shiftworkers
  • - Pregnancy and lactation
  • - Chronic medical condition, treatment, or medication other than diabetes that
  • may affect glucose metabolism (HIV diagnosis, use of steroids or
  • immunosuppressive drugs, etc.)
  • - 4 or more alcoholic drinks per day on a regular basis or use of recreational

研究者

发起方
TNO

相似试验